These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32597628)

  • 1. Identifying the Target of an Antiparasitic Compound in
    Herneisen AL; Sidik SM; Markus BM; Drewry DH; Zuercher WJ; Lourido S
    ACS Chem Biol; 2020 Jul; 15(7):1801-1807. PubMed ID: 32597628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoccidial kinase inhibitors: identification of protein kinase targets secondary to cGMP-dependent protein kinase.
    Donald RG; Zhong T; Wiersma H; Nare B; Yao D; Lee A; Allocco J; Liberator PA
    Mol Biochem Parasitol; 2006 Sep; 149(1):86-98. PubMed ID: 16765465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii.
    Rutaganira FU; Barks J; Dhason MS; Wang Q; Lopez MS; Long S; Radke JB; Jones NG; Maddirala AR; Janetka JW; El Bakkouri M; Hui R; Shokat KM; Sibley LD
    J Med Chem; 2017 Dec; 60(24):9976-9989. PubMed ID: 28933846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays.
    Scheele S; Geiger JA; DeRocher AE; Choi R; Smith TR; Hulverson MA; Vidadala RSR; Barrett LK; Maly DJ; Merritt EA; Ojo KK; Van Voorhis WC; Parsons M
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Plasmodium Atg3-Atg8 Interaction Inhibitors Identifies Novel Alternative Mechanisms of Action in Toxoplasma gondii.
    Varberg JM; LaFavers KA; Arrizabalaga G; Sullivan WJ
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity.
    Johnson SM; Murphy RC; Geiger JA; DeRocher AE; Zhang Z; Ojo KK; Larson ET; Perera BG; Dale EJ; He P; Reid MC; Fox AM; Mueller NR; Merritt EA; Fan E; Parsons M; Van Voorhis WC; Maly DJ
    J Med Chem; 2012 Mar; 55(5):2416-26. PubMed ID: 22320388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1.
    Moine E; Dimier-Poisson I; Enguehard-Gueiffier C; Logé C; Pénichon M; Moiré N; Delehouzé C; Foll-Josselin B; Ruchaud S; Bach S; Gueiffier A; Debierre-Grockiego F; Denevault-Sabourin C
    Eur J Med Chem; 2015 Nov; 105():80-105. PubMed ID: 26479029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.
    Larson ET; Ojo KK; Murphy RC; Johnson SM; Zhang Z; Kim JE; Leibly DJ; Fox AM; Reid MC; Dale EJ; Perera BG; Kim J; Hewitt SN; Hol WG; Verlinde CL; Fan E; Van Voorhis WC; Maly DJ; Merritt EA
    J Med Chem; 2012 Mar; 55(6):2803-10. PubMed ID: 22369268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture.
    Kuhlenschmidt TB; Rutaganira FU; Long S; Tang K; Shokat KM; Kuhlenschmidt MS; Sibley LD
    Antimicrob Agents Chemother; 2016 Jan; 60(1):570-9. PubMed ID: 26552986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The calcium-dependent protein kinase 1 from Toxoplasma gondii as target for structure-based drug design.
    Cardew EM; Verlinde CLMJ; Pohl E
    Parasitology; 2018 Feb; 145(2):210-218. PubMed ID: 29191253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis.
    Janetka JW; Hopper AT; Yang Z; Barks J; Dhason MS; Wang Q; Sibley LD
    J Med Chem; 2020 Jun; 63(11):6144-6163. PubMed ID: 32420739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection.
    Doggett JS; Ojo KK; Fan E; Maly DJ; Van Voorhis WC
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3547-9. PubMed ID: 24687502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.
    Vidadala RS; Rivas KL; Ojo KK; Hulverson MA; Zambriski JA; Bruzual I; Schultz TL; Huang W; Zhang Z; Scheele S; DeRocher AE; Choi R; Barrett LK; Siddaramaiah LK; Hol WG; Fan E; Merritt EA; Parsons M; Freiberg G; Marsh K; Kempf DJ; Carruthers VB; Isoherranen N; Doggett JS; Van Voorhis WC; Maly DJ
    J Med Chem; 2016 Jul; 59(13):6531-46. PubMed ID: 27309760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal and thermal profiling of the
    Herneisen AL; Li ZH; Chan AW; Moreno SNJ; Lourido S
    Elife; 2022 Aug; 11():. PubMed ID: 35976251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imidazopyridazine Inhibitors of Plasmodium falciparum Calcium-Dependent Protein Kinase 1 Also Target Cyclic GMP-Dependent Protein Kinase and Heat Shock Protein 90 To Kill the Parasite at Different Stages of Intracellular Development.
    Green JL; Moon RW; Whalley D; Bowyer PW; Wallace C; Rochani A; Nageshan RK; Howell SA; Grainger M; Jones HM; Ansell KH; Chapman TM; Taylor DL; Osborne SA; Baker DA; Tatu U; Holder AA
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1464-75. PubMed ID: 26711771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The calcium-dependent protein kinase 3 of toxoplasma influences basal calcium levels and functions beyond egress as revealed by quantitative phosphoproteome analysis.
    Treeck M; Sanders JL; Gaji RY; LaFavers KA; Child MA; Arrizabalaga G; Elias JE; Boothroyd JC
    PLoS Pathog; 2014 Jun; 10(6):e1004197. PubMed ID: 24945436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis.
    Castellanos-Gonzalez A; White AC; Ojo KK; Vidadala RS; Zhang Z; Reid MC; Fox AM; Keyloun KR; Rivas K; Irani A; Dann SM; Fan E; Maly DJ; Van Voorhis WC
    J Infect Dis; 2013 Oct; 208(8):1342-8. PubMed ID: 23878324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxoplasma DJ-1 Regulates Organelle Secretion by a Direct Interaction with Calcium-Dependent Protein Kinase 1.
    Child MA; Garland M; Foe I; Madzelan P; Treeck M; van der Linden WA; Oresic Bender K; Weerapana E; Wilson MA; Boothroyd JC; Reese ML; Bogyo M
    mBio; 2017 Feb; 8(1):. PubMed ID: 28246362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiparasitic Activity of Sulfur- and Fluorine-Containing Bisphosphonates against Trypanosomatids and Apicomplexan Parasites.
    Galaka T; Ferrer Casal M; Storey M; Li C; Chao MN; Szajnman SH; Docampo R; Moreno SN; Rodriguez JB
    Molecules; 2017 Jan; 22(1):. PubMed ID: 28054995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspective on current and emerging drugs in the treatment of acute and chronic toxoplasmosis.
    Lapinskas PJ; Ben-Harari RR
    Postgrad Med; 2019 Nov; 131(8):589-596. PubMed ID: 31399001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.